A team of researchers at the University of Bristol has achieved a breakthrough in regenerative medicine: the first 3D-printed functional human heart tissue that beats synchronously. The feat, published in the journal Advanced Functional Materials, marks a significant step toward creating transplantable organs.
The team, led by Professor Adam Perriman of the School of Cellular and Molecular Medicine, used a novel bio-ink made from stem cells reprogrammed into heart muscle cells. The cells are suspended in a hydrogel that mimics the extracellular matrix. The printer deposits the bio-ink in layers, building a structure that self-organises into functioning tissue.
“This is the first time anyone has printed an entire heart tissue construct that contracts spontaneously and responds to electrical stimulation,” Perriman told The British Wire. “It is a major step forward.”
The tissue, about the size of a one-pence coin, contains both heart muscle cells and blood vessel cells. It generates its own electrical impulses and beats at a rate similar to a human heart. When treated with drugs such as isoprenaline, it responded as natural tissue would.
The potential applications are vast. For drug testing, companies could use the printed tissue to screen for cardiac toxicity, replacing animal models. For regenerative medicine, the goal is to produce patches for damaged hearts after heart attacks.
“The dream is to print a whole human heart,” said Dr. Sanjay Sinha, a cardiologist at the University of Cambridge who was not involved in the study. “But we are still far from that. This is an elegant proof of concept.”
The printer, built by the team, uses a technique called “high-resolution 3D printing” with nozzles that are finer than a human hair. The cells remain viable and function for up to four months.
But challenges remain. The tissue is small and lacks the complex vasculature of a full organ. Scaling up will require new printing methods and more cells. Regulatory hurdles also lie ahead.
“Safety is paramount,” said Perriman. “We must ensure the tissue is stable, non-immunogenic, and integrates with the body.”
The university has filed patents and is seeking commercial partners. The team plans to test the tissue in animal models within two years.
For now, the beating tissue sits in a Petri dish. But its implications for medicine are profound.
